CD274 and non-small cell lung carcinoma: For patients with advanced NSCLC expressing PD-L1 of at least 50%, the results from several randomized studies indicate that ICI monotherapy is superior to chemotherapy in terms of both survival benefits and toxicity profile [14,24].